1. Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
- Author
-
Quiroga, Borja, Soler, María José, Ortiz, Alberto, Jaravaca Mantecón, Carlos Jesús, Nava Pérez, Nathasha, Serra Martín, Marta, Sato, Yurika, Marin Franco, Antonio José, Pazmiño Zambrano, Diana Flor, Lucena Valverde, Rafael, Ortega Diaz, Mayra, Calderón González, Carmen, Cazorla López, Juan Manuel, Pereira, Mónica, González Parra, Emilio, Sánchez Horrillo, Ana, Sánchez González, Carmen, Toapanta, Néstor, Cigarrán Guldris, Secundino, Sánchez Hernández, Rosa, Pizarro Sánchez, Soledad, Muñiz Rincón, María, Garcia-Fernández, Nuria, Blanco Castro, Natalia, Collantes Mateo, Rocío, Quiroz Morales, Manuel Augusto, Escamilla-Cabrera, Beatriz, Berdud Godoy, Isabel, Gil-Casares Casanova, Beatriz, Leyva, Alba, Rojas, José, Gansevoort, Ron T, de Sequera, Patricia, SENCOVAC collaborative network, Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Institut Català de la Salut, [Quiroga B] IIS-La Princesa, Nephrology Department, Hospital Universitario de la Princesa, Madrid, Spain. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ortiz A] IIS-Fundación Jiménez Diaz, School of Medicine, Universidad Autónoma de Madrid, Fundación Renal Iñigo Álvarez de Toledo-IRSIN, REDinREN, Instituto de Investigación Carlos III, Madrid, Spain. [Jaravaca Mantecón CJ, Nava Pérez N] Diaverum Andalucía, Spain. [Serra Martín M] Diaverum Valencia, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
técnicas de investigación::técnicas inmunológicas::inmunización::inmunoterapia activa::vacunación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Transplantation ,Investigative Techniques::Immunologic Techniques::Immunization::Immunotherapy, Active::Vaccination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,hemodialysis ,SARS-CoV-2 ,terapéutica::tratamiento de reemplazo renal::diálisis renal [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,COVID-19 ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,vaccination ,Hemodiàlisi ,COVID-19 VACCINATION ,Immunització ,NEUTRALIZING ANTIBODIES ,Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] ,Nephrology ,Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral [CHEMICALS AND DRUGS] ,aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos [COMPUESTOS QUÍMICOS Y DROGAS] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,booster ,Therapeutics::Renal Replacement Therapy::Renal Dialysis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,COVID-19 (Malaltia) - Vacunació ,Other subheadings::Other subheadings::/complications [Other subheadings] - Abstract
Background Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. Methods This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. Results A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001). Conclusions In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.Lay Summary Patients on hemodialysis present higher rates of complications derived from SARS-CoV-2 infections. Initial vaccination schedules have demonstrated suboptimal responses in those patients. The aim of the present study is to evaluate the time-course of the humoral response after a booster dose of SARS-CoV-2 RNA-based vaccines (BNT162b2 or mRNA-1273) in patients on hemodialysis. We included 711 patients that had received a booster dose: 545 (77%) 6 months before the initial vaccination and 166 (23%) between 6 and 9 months from the initial vaccination. After the booster, only 6 (
- Published
- 2022
- Full Text
- View/download PDF